Bio-Techne Corp
NASDAQ:TECH
Net Margin
Bio-Techne Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Bio-Techne Corp
NASDAQ:TECH
|
8.2B USD |
11%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
156.6B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
136B USD |
16%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.8B CHF |
10%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
238.5B CNY |
27%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.4B USD |
18%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28B USD |
9%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.8B USD |
22%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18.5B EUR |
7%
|
Bio-Techne Corp
Glance View
Bio-Techne Corp. began its journey with a clear focus: to bridge the gap between biological research and practical applications, a mission that it continues to pursue with zeal. At its core, Bio-Techne operates as a pioneer in the production and distribution of biotechnology products, catering to the needs of the scientific community across the globe. The company specializes in providing essential tools for life sciences research, including proteins, antibodies, and reagents, empowering researchers to explore and innovate in fields ranging from cancer biology to neuroscience. These offerings are developed with meticulous care and a deep understanding of the scientific process, which positions Bio-Techne as a trusted ally to laboratories and research institutions worldwide. The financial heartbeat of Bio-Techne lies in its diverse portfolio, which extends into clinical diagnostics and genomics, segments that are critical in an era of personalized medicine and rapid technological advancement in healthcare. The company's revenue streams are robust, driven by a strategic blend of direct sales and collaborations with major pharmaceutical and biotech companies. Furthermore, Bio-Techne smartly leverages its acquisitions to fortify its market position, enhancing its capabilities and expanding its product lines. This agility and foresight not only enable Bio-Techne to sustain its growth trajectory but also to continually meet the ever-evolving demands of a fast-paced, innovation-driven industry.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Bio-Techne Corp's most recent financial statements, the company has Net Margin of 10.9%.
You don't have any saved screeners yet